Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female adult (≥ 60 years)~2. Subject is contractually capable, able to understand information on study and has signed informed consent sheet~3. Subject has access to an internet-enabled electronic device~Exclusion Criteria:~1. Known active or latent Mycobacterium tuberculosis infection~2. Fever (\> 38 °C) or respiratory tract infection within the past 24 hours~3. Current active viral or bacterial infection~4. Expected vaccination during the study period; vaccinations against influenza and pneumococcal disease are allowed with ≥ 4 weeks between these vaccinations and the trial vaccination~5. Participation in another interventional study within 30 days before screening and during this study~6. Known hypersensitivity or allergy to (components of) the VPM1002 vaccine or serious adverse reactions to prior Bacille Calmette-Guérin (BCG) administration~7. Severely immunocompromised subjects, including:~   1. subjects with known infection by the human immunodeficiency virus (HIV-1);~  2. subjects with solid organ transplantation;~  3. subjects with bone marrow transplantation;~  4. subjects under chemotherapy, immunotherapy, or radiotherapy;~  5. subjects with primary immunodeficiency;~  6. treatment with any anti-cytokine therapies;~  7. treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months, or likely use of oral or intravenous steroids in the next 4 weeks;~8. History of malignancies, unless the subject has been free of the disease for ≥ 2 years; exception: subjects with adequately treated basal or squamous cell cancer or other localized non-melanoma skin cancer and adequately treated carcinoma in situ of the cervix may participate in the trial~9. Previous positive SARS-CoV-2 test result~10. Person is an employee of the sponsor, a relative of the sponsor or investigator, or is employed in the same department as the investigator

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- VPM1002 (Type: EXPERIMENTAL): The active ingredient of the recombinant BCG vaccine, VPM1002, is Mycobacterium bovis rBCGΔureC::hly, freeze-dried and standardized to the number of viable mycobacteria (colony forming units; CFU) per application.~Dose: 2-8 x 10e5 CFU VPM1002 administered in 0.1 ml reconstituted suspension.
- Placebo (Type: PLACEBO_COMPARATOR): Physiological saline 0.1ml

Based on this trial design, predict the completion outcome and termination type (if applicable).